80 CHAPTER 5 S3: CHARACTERISTICS OF ALL PATIENTS WITH ATRIAL FIBRILLATION WHO WERE PRESCRIBED ANTICOAGULATION THERAPY, A PLATELET INHIBITOR OR NO ANTITHROMBOTIC THERAPY AT ALL IN 2017 (STRATIFIED BY CHA2DS2-VASC SCORE). Variable CHA2DS2-VASc <2 CHA2DS2-VASc ≥2 ACT (n=33) PI (n=75) No ATT (n=539) ACT (n=3,014) PI (n=385) No ATT (n=766) Male sex 299(89.8) 63(84.0) 422(78.3) 1,422 (47.2) 193 (50.1) 335 (43.7) Age in years 62(56-68) 60(55-67) 55(46-62) 79(72-84) 78(70.5-85) 77(70-84) Age ≥75 years 0(0.0) 0(0.0) 0(0.0) 1,975 (65.5) 238(61.8) 458(59.8) CHA2DS2-VASc score 1 (0-1) 1 (0-1) 0 (0-1) 4 (3-5) 4 (3-5) 3 (2-5) Heart failure 9 (2.7) 0 (0.0) 2 (0.4) 766 (25.4) 62 (16.1) 176 (23.0) Hypertension 57(17.1) 12(16.0) 61(11.3) 2,022 (67.1) 270(70.1) 499(65.1) Diabetes mellitus 11 (3.3) 1 (1.3) 12 (2.2) 855 (28.4) 99 (25.7) 184 (24.0) CVA or TIA 0 (0.0) 0 (0.0) 0 (0.0) 523 (17.4) 84 (21.8) 96 (12.5) Vascular diseasea 9 (2.7) 6 (8.0) 5 (0.9) 883 (29.3) 173 (44.9) 183 (23.9) Renal impairmentb 21 (6.3) 3 (4.0) 3 (0.6) 902 (29.9) 110 (28.6) 185 (24.2) Dementia 1 (0.3) 0 (0.0) 0 (0.0) 122 (4.0) 15 (3.9) 52 (6.8) Asthma or COPD 47 (14.1) 9 (12.0) 66 (12.2) 659 (21.9) 76 (19.7) 169 (22.1) Malignancyc 17 (5.1) 8 (10.7) 14 (2.6) 410 (13.6) 36 (9.4) 90 (11.7) History of bleedingd 85(25.5) 17(22.7) 73(13.5) 1,028 (34.1) 114(29.6) 215(28.1) Beta blocker 238(71.5) 37(49.3) 119(22.1) 2,127 (70.6) 220(57.1) 278(36.3) Calcium channel blocker 50 (15.0) 5 (6.7) 18 (3.3) 790 (26.2) 89 (23.1) 107 (14.0) Digoxin 38 (11.4) 2 (2.7) 6 (1.1) 581 (19.3) 25 (6.5) 43 (5.6) Data are n (%) or median (interquartile range). a Coronary artery disease or peripheral vascular (arterial or venous) disease. b International Classification of Primary Care (ICPC) code U99.01 (renal impairment) or estimated glomerular filtration rate <60 mL/min/1.73 m2. c Five most prevalent malignancies in the Netherlands (apart from skin cancer): breast cancer, prostate cancer, colon cancer, lung cancer, and haematological cancer. d Posttraumatic extradural/subdural/intracerebral haemorrhage, haemoptysis, epistaxis, haematemesis, melaena, haematochezia, haematuria, menorrhagia, postpartum haemorrhage. ACT: anticoagulation therapy (i.e. a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant); ATT: antithrombotic therapy; COPD: chronic obstructive pulmonary disease; CVA: cerebrovascular accident; n: number; PI: platelet inhibitor; TIA: transient ischemic attack.
RkJQdWJsaXNoZXIy MTk4NDMw